Авторы

  • Зоиров Ш.Г., Махмудова А.Д., Ассесорова Ю.Ю., Исламов М.С.

Ключевые слова:

хроничекий миелолейкоз, распространенность, эпидемиологические аспекты, лечение.

Библиографические ссылки

Baccarani M, Deininger MW, Rosti G, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122(6):872–84. doi: 10.1182/blood-2013-05-501569.

Baccarani M, Pileri S, Steegmann JL, et al. Chronic myeloid leukemia: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2012;23(Suppl 7):vii72–7. doi: 10.1093/ annonc/mds228.

Baccarani M., Cortes J., Pane F. et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European Leukemia Net. J Clin Oncol 2009 Dec 10; 27(35): 6041–51. DOI: 10.1200/JCO.2009.25.0779. Epub 2009 Nov 2. PMID: 19884523.

Baccarani M., Pileri S., Steegmann J.-L. et al. on behalf of the ESMO Guidelines Working Group. Chronic myeloid leukemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012;23 (suppl 7):vii72 – vii77. DOI: 10.1093/annonc/mds228.

Bayrak AG, Daglar Aday A, Yavuz AS, et al. Overview of clinical and genetic features of CML patients with variant Philadelphia translocations involving chromosome 7: A case series. Leuk Res. 2021 Dec; 111:106725. doi: 10.1016/j.leukres.2021.106 725.

Beinortas T, Tavorienė I, Žvirblis T, et al. Chronic myeloid leukemia incidence, survival and accessibility of tyrosine kinase inhibitors: a report from population-based Lithuanian haematological disease registry 2000-2013. BMC Cancer. 2016 Mar 8;16:198. doi: 10.1186/s12885-016-2238-9. PMID: 26956037; PMCID: PMC4782571.

Bennour A, Bellâaj H, Ben Youssef Y, et al. Molecular cytogenetic characterization of Philadelphia-negative rearrangements in chronic myeloid leukemia patients. J Cancer Res Clin Oncol. 2011 Sep; 137(9):1329-36. doi: 10.1007/s00432-011-1002-4.

Bhardwaj M, Mishra SK, Gupta A, et al. Three-way Philadelphia Translocation [t(46, XX, t(9;22;16) (q34;q11.2;q24)] in Chronic Myeloid Leukemia: A Report of Two Cases with Review of the Literature. J Cancer Res Ther. 2024 Apr 1;20(3):1066-1070. doi: 10.4103/jcrt.jcrt_274_21.

Branford S, Dong D, Kim H, et al. Laying the foundation for genomical-ly-based risk assessment in chronic myeloid leukemia behalf of the International CML Foundation Genomics Alliance. Leukemia. 2019;33(8):1835–50. doi: 10.1038/s41375-019-0512-y

Branford S, Wang P, Yeung DT, et al. Integrative genomic analysis reveals cancer-associated mutations at diagnosis of CML in patients with high-risk dis-ease. Blood. 2018;132(9):948–61. doi: 10.1182/blood-2018-02-832253.

Branford S. Chronic myeloid leukemia: molecular monitoring in clinical practice. Hematology Am Soc Hematol Educ Program 2007:376–83.

Braun TP, Eide CA, Druker BJ. Response and Resistance to BCR-ABL1-Targeted Therapies. Cancer Cell. 2020 Apr 13;37(4):530-542. doi: 10.1016/j.ccell.2020.03.006. PMID: 32289275; PMCID: PMC7722523.

Brummendorf TH, Cortes JE, de Souza CA, Guilhot F, Duvillie L, Pavlov D, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukaemia: results from the 24-month follow-up of the BELA trial. Br J Haematol. 2015;168(1):69–81.

Chen Y, Wang H, Kantarjian H, Cortes J. Trends in chronic myeloid leukemia incidence and survival in the United States from 1975 to 2009. Leuk

Ciftciler R, Saglam EA, Inanc A, et al. A unique case of complex variant translocation of t(6;9;22)(p22;q34;q11.2), der(19) in a newly diagnosed patient with chronic myeloid leukemia. Cancer Genet. 2019 Sep; 237:78-81. doi: 10.1016/j.cancergen.2019.06.008.

Copland M. Treatment of blast phase chronic myeloid leukaemia: A rare and challenging entity. Br J Haematol. 2022 Dec;199(5):665-678. doi: 10.1111/bjh.18370. Epub 2022 Jul 22. PMID: 35866251; PMCID: PMC9796596.

Cortes J, Talpaz M, Bixby D, Deininger M, Shah N, Flinn IW, et al. A Phase 1 Trial of Oral Ponatinib (AP24534) In Patients with Refractory Chronic Myelogenous Leukemia (CML) and Other Hematologic Malignancies: Emerging Safety and Clinical Response Findings. Blood. 2010; 116(21): 210.20304810

Cross NCP, Ernst T, Branford S, et al. European LeukemiaNet laboratory recommendations for the diagnosis and management of chronic myeloid leukemia. Leukemia. 2023 Nov;37(11):2150-2167. doi: 10.1038/s41375-023-02048-y.

Esan OA, Senft JR, Wenger SL. Patterns of BCR/ABL Gene Rearrangements in Chronic Myeloid Leukemia with Complex t(9;22) Using Fluorescence In Situ Hybridization (FISH). J Assoc Genet Technol. 2012;38(1):5-7. PMID: 22421568.

Eskazan AE, Keskin D. Radotinib and its clinical potential in chronic-phase chronic myeloid leukemia patients: an update. Ther Adv Hematol. 2017 Sep; 8(9):237-243. doi: 10.1177/204062071 7719851.

Ganguly S, Sasi A, Pushpam D, Bakhshi S. Philadelphia Chromosome Positive and Philadelphia-Like Acute Lymphoblastic Leukemia in Children and Adolescents: Current Management, Controversies and Emerging Concepts. Indian J Pediatr. 2024 Jan;91(1):37-46. doi: 10.1007/s12098-023-04782-8.

Gong Z, Medeiros LJ, Cortes JE, et al. Cytogenetics-based risk prediction of blastic transformation of chronic myeloid leukemia in the era of TKI therapy. Blood Adv. 2017 Dec 8;1(26):2541-2552. doi: 10.1182/bloodadvances.2017011858.

Hasanova A, Asadov C, Karimova N, et al. Spectrum of BCR-ABL mutations in Azerbaijanian imatinib-resistant patients with chronic myeloid leukemia. Pathol Oncol Res. 2023 Dec 22;29:1611518. doi: 10.3389/pore.2023.1611518.

Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118(3):686–92. doi: 10.1182/blood-2010-12-319038

Hoffmann VS, Hasford J, Deininger M, Cortes J, Baccarani M, Hehlmann R. Systematic review and meta-analysis of standard-dose imatinib vs. high-dose imatinib and second generation tyrosine kinase inhibitors for chronic myeloid leukemia. J Cancer Res Clin Oncol. 2017;143(7):1311–8.

Höglund M, Sandin F, Simonsson B. Epidemiology of chronic myeloid leukaemia: an update. Ann Hematol. 2015 Apr;94 Suppl 2:S241-7. doi: 10.1007/s00277-015-2314-2.

Hughes T, Deininger MW, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108:28–37.

International statistical classification of diseases and related health problems (ICD-10). 10th revision. Volume 2. Instruction manual. Sixth Edition. 2019. – 275 р.

Işık S, Günden G, Üsküdar Teke H, et al. The Impact of Cytogenetic Aberrations in the Clonal Evolution of Chronic Myeloid Leukemia: A Single-Center Experience Among 450 Turkish Patients (Cohort Study). Turk J Haematol. 2022 Dec 1;39(4):237-244. doi: 10.4274/tjh.galenos.2022.2022.0045.

Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol. 2022 Sep;97(9):1236-1256. doi: 10.1002/ajh.26642. Epub 2022 Jul 6. PMID: 35751859.

Jabbour E., Branford S., Saglio G. et al. Practical advice for determining the role of BCR-ABL mutations in guiding tyrosine kinase inhibitor therapy in patients with chronic myeloid leukemia. Cancer 2011 May 1;117(9):1800–11. DOI: 10.1002/cncr. 25717.

Kantarjian H, Cortes J, Kim DW, et al. Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up. Blood. 2009 Jun 18;113(25):6322-9. doi: 10.1182/blood-2008-11-186817.

Kantarjian H, Giles F, Wunderle L, Bhalla K, O’Brien S, Wassmann B, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006;354(24):2542–51.

Kantarjian HM, Deininger MW, Abruzzese E, et al. Efficacy and Safety of Ponatinib (PON) in Patients with Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Who Failed One or More Second-Generation (2G) Tyrosine Kinase Inhibitors (TKIs): Analyses Based on PACE and Optic. Blood. 2020;136(Supplement 1):43–4.

Kim S-H, Menon H, Jootar S, et al. Efficacy and safety of radotinib in chronic phase chronic myeloid leukemia patients with resistance or intolerance to BCR-ABL1 tyrosine kinase inhibitors. Haematologica 2014; 99: 1191–1196.

Kwak J-Y, Kim H, Kim JA, et al. Efficacy and safety of radotinib compared with imatinib in newly diagnosed chronic phase chronic myeloid leukemia patients: 12 months result of phase 3 clinical trial. Blood 2015; 126: abstract 476.

Latifi Y, Moccetti F, Wu M, Xie A, Packwood W, Qi Y, et al. Thrombotic microangiopathy as a cause of cardiovascular toxicity from the BCR-ABL1 tyrosine kinase inhibitor ponatinib. Blood. 2019; 133 (14): 1597–606.

Абдулкадыров К.М., Шуваев В.А., Мартынкевич И.С. Миелопролиферативные новообразования. М.: Литтерра, 2016. - 298 с

Афанасьев Б.В., Абдуллаев А.О., Аль-Ради Л.С., и др. Клинические рекомендации «Хронический миелолейкоз». Разработчики: Общероссийский национальный союз "Ассоциация онкологов России", Некоммерческое партнерство содействия развитию гематологии и трансплантологии костного мозга "Национальное гематологическое общество". – 2020. – 87 с.

Зельцер А.Н., Бурнашева Е.В., Шатохин Ю.В. Молекулярно-генетическая характеристика хронического миелоидного лейкоза. Журнал фундаментальной медицины и биологии, 2016. (1), 4-14.

Лазарева О.В., Туркина А.Г., Челышева Е.Ю. и др. Клинико-гематологическая характеристика больных при диагностике хронического миелолейкоза: Анализ российских данных в рамках международного популяционного исследования (Population Based Study). Гематология и трансфузиология. 2016;61(1 Suppl 1):136–7.

Мисюрин А.В, Мисюрина Е.Н., Тихонова В.В., и др. (2016). Частота встречаемости мутаций киназного домена гена bcr-abl у больных хроническим миелолейкозом, резистентных к терапии иматинибом // Российский биотерапевтический журнал. 2016. -15 (4). -С.102-109.

Николаев Н.А., Мартынов А.И., Скирденко Ю.П., и др. Управление лечением на основе приверженности // Consilium Medicum. – 2020. 22 (5), 9-18.

Туркина А.Г., Зарицкий А.Ю., Шуваев В.А., и др. Клинические рекомендации по диагностике и лечению хронического миелолейкоза. Клиническая онкогематология. Фундаментальные исследования и клиническая практика, 2017. 10 (3), 294-316.